Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany


Products for every stage of the reproductive cycle
We are the world leader in fertility treatment. We strive to develop and market innovative, easy-to-use products to help infertile couples at every stage of the reproductive cycle, from follicular development to early pregnancy.
We recently introduced a “Family of Pens” in response to feedback from healthcare professionals and patients. By providing a common injection platform for our gonadotropins, we hope to faciltate patient training and ease of use. Launched in 2011, the family of pens complements our existing injection devices and pre-filled pens. The new family of pens delivery devices are not available in all markets.

Our company is the only drug-maker to offer a full portfolio of fertility drugs for every stage of the reproductive cycle and recombinant versions of the three hormones needed to treat infertility:
  • Recombinant human follicle stimulating hormone (GONAL-f®)
  • Recombinant human luteinizing hormone (Luveris®)
  • Recombinant human chorionic gonadotropin (Ovidrel®/Ovitrelle®)
  • Combined recombinant human follicle stimulating hormone and recombinant human luteinizing hormone (Pergoveris®)
  • Progesterone gel  (Crinone® 8%)
  • Cetrorelix acetate (Cetrotide®)

With this complete portfolio, we offer physicians the ability to tailor treatment to individual patients.

With an estimated 1.8 million babies born thanks to our innovative products, we have helped thousands of infertile couples to realize their dream of having a child. We continue to pursue focused research and development in order to offer patients the fertility treatments of tomorrow.


The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.


Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.